ArticleRSC chemical biology2022
Development of a NanoBRET assay to validate inhibitors of Sirt2-mediated lysine deacetylation and defatty-acylation that block prostate cancer cell migration.
Open access · goldAbstract read
In one paragraph
Article in RSC chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Design, Synthesis, and Biological Evaluation of Pyrazolyl Thioureas (PTUs) as SIRT1 and SIRT2 Inhibitors.ChemMedChem · 2026Article
- Structure-Guided Optimization and Biological Validation of 1,3,4-Thiadiazole-Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions.Drug development research · 2026Article
- Cellular Target Engagement and Dissociation Kinetics of Class I-Selective Histone Deacetylase (HDAC) Inhibitors.International journal of molecular sciences · 2026Article
- From Pharmacophore to Warhead: NADAngewandte Chemie (International ed. in English) · 2025Article
- Lead Structure-Based Hybridization Strategy Reveals Major Potency Enhancement of SirReal-Type Sirt2 Inhibitors.International journal of molecular sciences · 2025Article
- Target Engagement Studies and Kinetic Live-Cell Degradation Assays Enable the Systematic Characterization of Histone Deacetylase 6 Degraders.ACS pharmacology & translational science · 2025Article
- Efficient Crystallization of Apo Sirt2 for Small-Molecule Soaking and Structural Analysis of Ligand Interactions.Journal of medicinal chemistry · 2025Article
- Molecular Sentinels: Unveiling the Role of Sirtuins in Prostate Cancer Progression.International journal of molecular sciences · 2024Review
- Symmetrical 2,7-disubstituted 9H-fluoren-9-one as a novel and promising scaffold for selective targeting of SIRT2.Archiv der Pharmazie · 2024Article
- A homogeneous time-resolved fluorescence screen to identify SIRT2 deacetylase and defatty-acylase inhibitors.PloS one · 2024Article
- Structure, functions, and recent advances in the development of SIRT2 inhibitors.Pharmaceutical science advances · 2023Review
- Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation.Journal of medicinal chemistry · 2023Article
- Continuous Fluorescent Sirtuin Activity Assay Based on Fatty Acylated Lysines.International journal of molecular sciences · 2023Article
- Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACs.ACS pharmacology & translational science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
A VogelmannInstitute of Pharmaceutical Sciences, University of Freiburg Albertstraße 25 79104 Freiburg Germany manfred.jung@pharmazie.uni-freiburg.de.ORCID https://orcid.org/0000-0001-5266-0295
M SchiedelDepartment of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-University Erlangen-Nürnberg Nikolaus-Fiebiger-Straße 10 91058 Erlangen Germany.ORCID https://orcid.org/0000-0001-7365-3617
N WössnerInstitute of Pharmaceutical Sciences, University of Freiburg Albertstraße 25 79104 Freiburg Germany manfred.jung@pharmazie.uni-freiburg.de.
A MerzInstitute of Pharmaceutical Sciences, University of Freiburg Albertstraße 25 79104 Freiburg Germany manfred.jung@pharmazie.uni-freiburg.de.
D HerpInstitute of Pharmaceutical Sciences, University of Freiburg Albertstraße 25 79104 Freiburg Germany manfred.jung@pharmazie.uni-freiburg.de.
S HammelmannInstitute of Pharmaceutical Sciences, University of Freiburg Albertstraße 25 79104 Freiburg Germany manfred.jung@pharmazie.uni-freiburg.de.
A ColcerasaInstitute of Pharmaceutical Sciences, University of Freiburg Albertstraße 25 79104 Freiburg Germany manfred.jung@pharmazie.uni-freiburg.de.ORCID https://orcid.org/0000-0003-3491-2326
G KomanieckiDepartment of Chemistry and Chemical Biology, Cornell University Ithaca NY 14853 USA.
J Y HongDepartment of Chemistry and Chemical Biology, Cornell University Ithaca NY 14853 USA.
M SumDepartment of Urology and Center for Clinical Research, University of Freiburg Medical Center Breisacher Strasse 66 79106 Freiburg Germany.
E MetzgerDepartment of Urology and Center for Clinical Research, University of Freiburg Medical Center Breisacher Strasse 66 79106 Freiburg Germany.
E NeuwirtInstitute of Neuropathology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg 79106 Freiburg Germany.
L ZhangInstitute of Biochemistry, University of Freiburg Albertstraße 21 79104 Freiburg Germany.
O EinsleInstitute of Biochemistry, University of Freiburg Albertstraße 21 79104 Freiburg Germany.
O GroßInstitute of Neuropathology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg 79106 Freiburg Germany.
R SchüleDepartment of Urology and Center for Clinical Research, University of Freiburg Medical Center Breisacher Strasse 66 79106 Freiburg Germany.
H LinDepartment of Chemistry and Chemical Biology, Cornell University Ithaca NY 14853 USA.ORCID https://orcid.org/0000-0002-0255-2701
W SipplDepartment of Medicinal Chemistry, Institute of Pharmacy, University of Halle-Wittenberg Kurt-Mothes-Str. 3 06120 Halle Germany.ORCID https://orcid.org/0000-0002-5985-9261
M JungInstitute of Pharmaceutical Sciences, University of Freiburg Albertstraße 25 79104 Freiburg Germany manfred.jung@pharmazie.uni-freiburg.de.ORCID https://orcid.org/0000-0002-6361-7716
University of Freiburg · DECornell University · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHoward Hughes Medical Institute · USMartin Luther University Halle-Wittenberg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sirtuin2 (Sirt2) with its NAD
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.